5.06
0.07 (1.40%)
| Previous Close | 4.99 |
| Open | 5.04 |
| Volume | 8,926 |
| Avg. Volume (3M) | 28,596 |
| Market Cap | 9,712,376 |
| Price / Sales | 2.14 |
| Price / Book | 0.350 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2025 |
| Operating Margin (TTM) | -991.41% |
| Diluted EPS (TTM) | -33.20 |
| Quarterly Revenue Growth (YOY) | -76.80% |
| Total Debt/Equity (MRQ) | 52.79% |
| Current Ratio (MRQ) | 3.13 |
| Operating Cash Flow (TTM) | -57.90 M |
| Levered Free Cash Flow (TTM) | -34.68 M |
| Return on Assets (TTM) | -34.57% |
| Return on Equity (TTM) | -83.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Bolt Biotherapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.13 |
|
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.26% |
| % Held by Institutions | 46.17% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Nan Fung Group Holdings Ltd | 30 Sep 2025 | 58,347 |
| Board Of Trustees Of The Leland Stanford Junior University | 30 Sep 2025 | 35,978 |
| 52 Weeks Range | ||
| Median | 7.00 (38.34%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 Oct 2025 | 7.00 (38.34%) | Buy | 5.86 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Nov 2025 | Announcement | Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update |
| 01 Oct 2025 | Announcement | Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |